121 related articles for article (PubMed ID: 36563676)
1. Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma.
Wu RQ; Lao XM; Chen DP; Qin H; Mu M; Cao WJ; Deng J; Wan CC; Zhan WY; Wang JC; Xu L; Chen MS; Gao Q; Zheng L; Wei Y; Kuang DM
Immunity; 2023 Jan; 56(1):180-192.e11. PubMed ID: 36563676
[TBL] [Abstract][Full Text] [Related]
2.
Si W; Liang H; Bugno J; Xu Q; Ding X; Yang K; Fu Y; Weichselbaum RR; Zhao X; Wang L
Gut; 2022 Mar; 71(3):521-533. PubMed ID: 33685966
[TBL] [Abstract][Full Text] [Related]
3. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
4. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Lee YH; Tai D; Yip C; Choo SP; Chew V
Front Immunol; 2020; 11():568759. PubMed ID: 33117354
[TBL] [Abstract][Full Text] [Related]
5. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
[TBL] [Abstract][Full Text] [Related]
6. The sialylation profile of IgG determines the efficiency of antibody directed osteogenic differentiation of iMSCs by modulating local immune responses and osteoclastogenesis.
Wu Q; Yang Y; Xie D; Li S; Liu Y; Shu L; Fu G; Xu Y; Ji P
Acta Biomater; 2020 Sep; 114():221-232. PubMed ID: 32771590
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM; Lee RY; Goh S; Tay ISY; Lim X; Lee B; Chew V; Li H; Tan B; Lim S; Lim JCT; Au B; Loh JJH; Saraf S; Connolly JE; Loh T; Leow WQ; Lee JJX; Toh HC; Malavasi F; Lee SY; Chow P; Newell EW; Choo SP; Tai D; Yeong J; Lim TKH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847986
[TBL] [Abstract][Full Text] [Related]
8. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
[TBL] [Abstract][Full Text] [Related]
9. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene.
Jones MB; Nasirikenari M; Lugade AA; Thanavala Y; Lau JT
J Biol Chem; 2012 May; 287(19):15365-70. PubMed ID: 22427662
[TBL] [Abstract][Full Text] [Related]
11. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
Chuah S; Lee J; Song Y; Kim HD; Wasser M; Kaya NA; Bang K; Lee YJ; Jeon SH; Suthen S; A'Azman S; Gien G; Lim CJ; Chua C; Hazirah SN; Lee HK; Lim JQ; Lim TKH; Yeong J; Chen J; Shin EC; Albani S; Zhai W; Yoo C; Liu H; Choo SP; Tai D; Chew V
J Hepatol; 2022 Sep; 77(3):683-694. PubMed ID: 35430299
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
13. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
[TBL] [Abstract][Full Text] [Related]
14. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
15. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
16. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
17. Salmonella Induces the cGAS-STING-Dependent Type I Interferon Response in Murine Macrophages by Triggering mtDNA Release.
Xu L; Li M; Yang Y; Zhang C; Xie Z; Tang J; Shi Z; Chen S; Li G; Gu Y; Wang X; Zhang F; Wang Y; Shen X
mBio; 2022 Jun; 13(3):e0363221. PubMed ID: 35604097
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
[TBL] [Abstract][Full Text] [Related]
20. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.
Li A; Yi M; Qin S; Song Y; Chu Q; Wu K
J Hematol Oncol; 2019 Apr; 12(1):35. PubMed ID: 30935414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
